Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212489 | 0.78 | ALDH1A1 (0.65) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL970071 | 0.77 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL10054150 | 0.77 | KDM4E (0.64) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL10272059 | 0.73 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL10220036 | 0.73 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL8536020 | 0.73 | KDM4E (0.58) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL29454507 | 0.72 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL6693068 | 0.72 | SIRT1 (0.58) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL8534280 | 0.70 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10POLBMEN1 | |
| SCHEMBL9313310 | 0.69 | ADORA3 (0.58) | ALDH1A1KDM4EHSD17B10POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380817-B | Benzimidazolo 2-amino-1, 3, 4-thiadiazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-114380817-A | Benzimidazole 2-amino-1, 3, 4-thiadiazole compound and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | claimed |
| CN-114380817-B | Benzimidazolo 2-amino-1, 3, 4-thiadiazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-112279845-B | Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof | 中国医学科学院药物研究所 | 2023-07-28 | — | — | CN | disclosed |
| CN-114380817-A | Benzimidazole 2-amino-1, 3, 4-thiadiazole compound and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| CN-112279845-A | Aryl or heteroaryl substituted thiadiazole compounds and antibacterial application thereof | 中国医学科学院药物研究所 | 2021-01-29 | — | — | CN | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| CN-103154018-B | For passing through the antibody of affinity chromatography and the part of Fc-fusion protein purification | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-04-27 | — | — | CN | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| EP-2812346-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | Graffinity Pharmaceuticals GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013117707-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3000/4885KDM4E 3660/4885HSD17B10 4170/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3083/4885KDM4E 3539/4885HSD17B10 4166/4885 |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 4076/4885KDM4E 2501/4885HSD17B10 4441/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | ALDH1A1 2263/4885KDM4E 2705/4885HSD17B10 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.